{"id":390626,"date":"2018-07-13T00:00:00","date_gmt":"2018-07-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/paprim0001-2018-biopharma-rheumatoid-arthritis-patient-profiler-us-2018\/"},"modified":"2026-04-15T09:56:05","modified_gmt":"2026-04-15T09:56:05","slug":"paprim0001-2018-biopharma-rheumatoid-arthritis-patient-profiler-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/paprim0001-2018-biopharma-rheumatoid-arthritis-patient-profiler-us-2018\/","title":{"rendered":"Rheumatoid Arthritis | Patient Profiler  | US | 2018"},"content":{"rendered":"<p>Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded with efficacious biologics, including blockbuster tumor necrosis factor-alpha (TNF-\u03b1) inhibitors Amgen\u2019s Enbrel, AbbVie\u2019s Humira, and Janssen\u2019s Remicade, as well as non-TNF-\u03b1\u00a0inhibitors such as Bristol-Myers Squibb\u2019s Orencia\u00a0and\u00a0Roche\/Genentech\u2019s Rituxan and Actemra. In addition, Pfizer\u2019s Jak inhibitor Xeljanz, the first targeted oral molecule approved for RA, has been approved for more than\u00a0five years in the United States and is experiencing\u00a0steady uptake. The RA\u00a0therapy market is expected to become increasingly competitive\u00a0with the upcoming approvals of additional agents and the entry of biosimilars, making brand differentiation and understanding of key patient characteristics ever more critical for marketers.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What is the patient share in RA\u00a0of\u00a0TNF-\u03b1\u00a0inhibitors and other key drug classes?<\/li>\n<li>What are the demographic characteristics and clinical profiles of RA patients on biologics and Xeljanz?<\/li>\n<li>What are the key risk factors, comorbidities, and coprescribed\/additional therapies by patient segment for RA?<\/li>\n<li>How do RA patient cohorts compare in care utilization and outcomes (physician visits and other healthcare encounters)?<\/li>\n<li>What are the reimbursed and out-of-pocket costs?<\/li>\n<li>What kind of insurance do RA patients have?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Patient Profiler<\/em> provides disease-specific, patient-level analysis of key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG\u2019s comprehensive real-world data (RWD) repository.<\/p>\n","protected":false},"template":"","class_list":["post-390626","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390626\/revisions"}],"predecessor-version":[{"id":393750,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390626\/revisions\/393750"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}